This triple mechanism of action sets it apart from currently approved options such as semaglutide and tirzepatide, giving it the potential to produce even greater metabolic effects on appetite, energy expenditure, and fat metabolism
Consider the typical scenario for someone using a GLP-1 based compound alone
Participants with a BMI of 27 or higher were also included if they had at least one weight-related health condition, like high blood pressure, high cholesterol, or sleep apnea
HHS later referred the company to the Department of Justice after it announced the launch of a $49 version of Novo Nordisks Wegovy pill
Where Wegovy (semaglutide) targets one hormone receptor, and Mounjaro (tirzepatide) targets two, retatrutide targets three
GLP-1 patients generally retain more subcutaneous fat and have fewer nutritional deficiencies